Cancer Genetics (NASDAQ:CGIX) Coverage Initiated by Analysts at

Equities research analysts at started coverage on shares of Cancer Genetics (NASDAQ:CGIXGet Rating) in a research note issued to investors on Wednesday. The firm set a “sell” rating on the stock.

Cancer Genetics Stock Performance

Shares of CGIX opened at $0.26 on Wednesday. Cancer Genetics has a fifty-two week low of $2.11 and a fifty-two week high of $17.50. The company has a market capitalization of $1.06 million, a price-to-earnings ratio of -0.13 and a beta of 2.72. The firm has a 50-day simple moving average of $0.47 and a 200-day simple moving average of $0.82.

About Cancer Genetics

(Get Rating)

Vyant Bio, Inc is emerging as an advanced biotechnology drug discovery company. The firm is focused on human-powered scientific and technology-based systems to de-risk and accelerate the discovery and development of therapeutics for biopharma partners, as well as for its proprietary pipeline. The company with capabilities in data, science (both biology and chemistry), engineering, and regulatory, it rapidly identifying small and large molecule therapeutics and derisking decision making through multiple in silico, in vitro, and in vivo modalities.

Further Reading

Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with's FREE daily email newsletter.